BIAF: bioAffinity PEG Multiple

bioAffinity Technologies revenues are based on the B2B integration of CyPath into pulmonology centers. The P/E ratio divided by the growth rate visualizes the asset's fundamental value, where the 0.00 metric serves as the target level. Monetization relies on the non-invasive detection of cancer through sputum analysis. Business success depends on diagnostic accuracy and the rate of test adoption into medical practice.

Investors verify the issuer's reliability by comparing market value with net income dynamics to avoid overpaying for unjustified expectations. By analyzing the PEG ratio, you determine the cost of every percentage of expansion for bioAffinity Technologies (BIAF), where a value below one signals an undervalued business protected by CyPath Lung patents and strict FDA control.